Key Considerations for Commercializing a Compound - - BioPharm International

ADVERTISEMENT

Key Considerations for Commercializing a Compound


blog comments powered by Disqus


Joerg Zimmerman, director of process development and implementation at Vetter discusses the need to think carefully about the commercialization efforts that must be applied to a compound under development. Providing real world examples, Zimmerman runs through the technical challenges that biotech companies commonly face in drug development and offers some sound advice to facilitate the process. Zimmerman also talks on the regulatory focus on considering biological formulations in prefilled syringes as combination products and the need to establish compatibility at an early stage in development. Posted Feb. 2012.

Related article: Playing the Drug Development Game

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines

Click here